<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468064</url>
  </required_header>
  <id_info>
    <org_study_id>ZJH-001</org_study_id>
    <secondary_id>2011A030400007</secondary_id>
    <nct_id>NCT01468064</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke</brief_title>
  <acronym>AMETIS</acronym>
  <official_title>Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Patients With Ischemic Stroke: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second People's Hospital of Nanhai District of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Haizhu District Guangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cellonis Biotechnology Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility, efficacy, and safety of autologous
      transplantation of ex vivo expanded bone marrow stromal cells (BMSCs)and endothelial
      progenitor cells (EPCs) for treatment of patients with ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, single-blind, randomized, parallel controlled trail. Patients
      with acute cerebral infarcts within the middle cerebral arterial territory and with severe
      neurological deficits will be enrolled and randomly allocated into 3 groups: autologous BMSCs
      transplantation group, autologous EPCs transplantation group and Placebo control group.
      Randomization codes were established by the study statistician and were revealed only to the
      stem cell laboratory technician responsible for separating the cells into aliquots or
      preparing the placebo material. All patients will undergo a Bone Marrow aspiration procedure
      at 7 days after symptom onset. BMSCs and EPCs will be expanded ex vivo and then intravenously
      infused into own body, respectively. The control group will not receive cell therapy. Observe
      will followed for up to 1 year after the onset. Neurological score, neuroimaging, mortality
      of any cause, side effects, and new-onset comorbidities will be monitored and compared
      between each groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events after infusion of BMSCs or EPCs.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stroke</condition>
  <condition>Infarction, Middle Cerebral Artery</condition>
  <arm_group>
    <arm_group_label>BMSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EPCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous BMSCs transplantation</intervention_name>
    <description>The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.
The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.</description>
    <arm_group_label>BMSCs group</arm_group_label>
    <other_name>Autologous Bone marrow stromal cells transplantation</other_name>
    <other_name>Autologous Mesenchymal stem cells transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous EPCs transplantation</intervention_name>
    <description>The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.
The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.</description>
    <arm_group_label>EPCs group</arm_group_label>
    <other_name>Autologous endothelial progenitor cells transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>IV infusion of placebo</intervention_name>
    <description>IV infusion of saline plus 5% autologous serum.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Placebo control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 to 80 years, within 7 days of the onset of symptoms

          2. Ischemic lesion within the MCA territory as assessed using diffusion-weighted imaging
             (DWI)

          3. The National Institutes of Health Stroke Scale (NIHSS) â‰¥ 7 at day 7 after the onset

          4. Signed informed consent

        Exclusion Criteria:

          1. Lacunar syndrome

          2. Diagnosis other than ischemic stroke(eg. Intracranial hemorrhage or Intracranial
             tumor)

          3. Hematological causes of stroke

          4. Severe respiratory, hepatic, or renal disorders

          5. Presence of severe febrile illness or viral diseases

          6. Malignant diseases

          7. Presence of autoimmune diseases

          8. Positive response of penicillin skin test, or multiple drug allergies

          9. Breast-feeding or pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenzhou Chen, MD., phD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Zhujiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenzhou Chen, MD., phD.</last_name>
    <phone>+86-20-62782768</phone>
    <email>czz1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiquan Ke, MD., phD.</last_name>
    <phone>+86-20-61643266</phone>
    <email>kyquan@fimmu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhujiang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen-Zhou Chen, MD., phD.</last_name>
      <phone>+86-20-62782768</phone>
      <email>czz1020@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi-Quan Ke, MD., phD.</last_name>
      <phone>+86-20-61643266</phone>
      <email>kyquan@fimmu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhen-Zhou Chen, MD., phD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010 Jun;28(6):1099-106. doi: 10.1002/stem.430.</citation>
    <PMID>20506226</PMID>
  </reference>
  <reference>
    <citation>Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005 Jun;57(6):874-82.</citation>
    <PMID>15929052</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern Medical University, China</investigator_affiliation>
    <investigator_full_name>Zhen-Zhou Chen</investigator_full_name>
    <investigator_title>Department of Neurosurgery, Zhujiang Hospital</investigator_title>
  </responsible_party>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Stroke</keyword>
  <keyword>Infarction, Middle Cerebral Artery</keyword>
  <keyword>Cerebral Infarction</keyword>
  <keyword>Cerebrovascular Accident</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Mesenchymal Stem Cell Transplantation</keyword>
  <keyword>Bone marrow stromal cells</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Endothelial progenitor cells</keyword>
  <keyword>Adult Stem Cells</keyword>
  <keyword>Cell Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

